Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02424955 · ClinicalTrials.gov registry record · NA
Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT02424955: Completed NA study, sponsored by Stanford University.
NCT02424955 is a NA study that has completed, run by Stanford University. The registered enrollment target is 11 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02424955, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.
Primary Outcome
The purpose of this pilot project is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.
Interventions
- DRUG perflutren lipid microspheres
- DIAGNOSTIC_TEST 3D ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-11-18 |
| Est. Completion | 2022-06-30 |
| Phase | NA |
What the finished NCT02424955 record still lists
NCT02424955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which perflutren lipid microspheres is the first listed.
NCT02424955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02424955 about?
NCT02424955 is a clinical study titled "Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation". The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.
What is the current status of trial NCT02424955?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2014-11-18. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT02424955?
The interventions under investigation include: perflutren lipid microspheres (DRUG), 3D ultrasound (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02424955?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02424955's enrollment target sits among peer trials
11 1927th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI